The impact of dehydroepiandrosterone in poor ovarian responders on assisted reproduction technology treatment

JBRA Assist Reprod. 2019 Oct 14;23(4):414-417. doi: 10.5935/1518-0557.20190045.

Abstract

One in six couples worldwide will experience at least one infertility problem during their reproductive years. Between 5.6% and 35.1% of women will exhibit poor ovarian response. A variety of methods have been applied to improve ovarian response, including dehydroepiandrosterone. In the ovaries, dehydroepiandrosterone promotes follicular development and granulosa cell proliferation by increasing intraovarian androgen concentrations while simultaneously enhancing the level of follicular insulin-like growth factor-1, which promotes folliculogenesis. Dehydroepiandrosterone supplementation may improve in vitro fertilization outcomes and ovarian response in patients with poor ovarian response. However, a few questions still loom over the effectiveness of dehydroepiandrosterone.

Keywords: Bologna criteria; anti-Müllerian hormone; antral follicle count; dehydroepiandrosterone; in vitro fertilization; poor ovarian responder.

Publication types

  • Review

MeSH terms

  • Adult
  • Dehydroepiandrosterone / administration & dosage*
  • Female
  • Fertilization in Vitro / methods*
  • Humans
  • Infertility, Female / therapy*
  • Ovulation Induction / methods*
  • Pregnancy
  • Pregnancy Rate
  • Treatment Outcome

Substances

  • Dehydroepiandrosterone